Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study.
Journal: The Lancet. Microbe
Published: September 12, 2025
Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab.
Journal: The Journal of infectious diseases
Published: July 18, 2025
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial.
Journal: The lancet. HIV
Published: December 23, 2024
Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
Journal: The Journal of infectious diseases
Published: November 15, 2024
Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: March 14, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.
Journal: The lancet. HIV
Published: May 24, 2023
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Journal: AIDS (London, England)
Published: April 25, 2022
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals.
Journal: AIDS (London, England)
Published: September 29, 2021
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: March 18, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: November 16, 2020
Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti.
Journal: Journal of the International AIDS Society
Published: November 05, 2020
Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Journal: The Journal of antimicrobial chemotherapy
Published: September 30, 2020
Last Updated: 09/26/2026